Transgene Biotek Ltd 17 Nov 2026 12:00 AM
Transgene Biotek Ltd consolidated sales down remained flat on year in Q2FY2027,
Transgene Biotek Ltd`s net loss stood at Rs 0.35 crore in Q2FY2027 compared to a net loss of Rs 0.39 crore in Q2FY26. The revenue from operations remained flat to Rs 0.06 crore in Q2FY27 over Q2FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 82739.8 crore, advancing by 10.04%. It has marginally improved by 0.47% over last one week and ticked higher by 0.59% in last one month while the market capitalization of Transgene Biotek Ltd has eased by 3.14% and 10.93% in the same period respectively. Profit before tax (PBT) of Transgene Biotek Ltd stood at Rs 0.35 crore in Q2 FY27, dropping 10.26% year-on-year, and falling 10.26% quarter-on-quarter. EBITDA came in at Rs 0 crore, tumbling by 71.43% YoY and crashing by 66.67% sequentially. Total expenses saw a steep drop of 25% to Rs 0.12 crore in Q2FY27 over Q2FY26. During the quarter, employee benefits expense was at Rs 0.03 crore, remaining flat YoY. For FY26, revenue from operations rose 13.04% to Rs 0.26 crore, while net profit inched up 3.03% to Rs 0.68 crore, compared to previous FY. EBITDA tanked by 180% to Rs 1.91 crore, and PBT saw a minor gain of 3.03% to Rs 0.68 crore compared to previous FY. Transgene Biotek Ltd tumbled by 35.79% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.35% during the same period.
Transgene Biotek Ltd 16 Nov 2026 12:00 AM
Transgene Biotek Ltd consolidated sales down remained flat on year in Q2FY2027,
Transgene Biotek Ltd`s net loss stood at Rs 0.35 crore in Q2FY2027 compared to a net loss of Rs 0.39 crore in Q2FY26. The revenue from operations remained flat to Rs 0.06 crore in Q2FY27 over Q2FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 83415.97 crore, improving 10.04%. It has marginally improved by 0.47% over last one week and dipped slightly by 0.23% in last one month while the market capitalization of Transgene Biotek Ltd has softened by 3.14% and 14.36% in the same period respectively. Profit before tax (PBT) of Transgene Biotek Ltd stood at Rs 0.35 crore in Q2 FY27, falling 10.26% year-on-year, and retreating 10.26% quarter-on-quarter. EBITDA came in at Rs 0 crore, crashing by 71.43% YoY and tumbling by 66.67% sequentially. Total expenses saw a steep drop of 25% to Rs 0.12 crore in Q2FY27 over Q2FY26. During the quarter, employee benefits expense was at Rs 0.03 crore, remaining flat YoY. For FY26, revenue from operations advanced 13.04% to Rs 0.26 crore, while net profit grew slightly 3.03% to Rs 0.68 crore, compared to previous FY. EBITDA tanked by 180% to Rs 1.91 crore, and PBT inched up 3.03% to Rs 0.68 crore compared to previous FY. Transgene Biotek Ltd nosedived by 32.31% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.42% during the same period.
Transgene Biotek Ltd 31 Oct 2026 12:00 AM
Transgene Biotek Limited’s statutory auditors, Eswara Rao & Co., resigned citing workload conflicts,
Transgene Biotek Limited informed the BSE Limited that M/s. Eswara Rao & Co., Chartered Accountants (Firm Registration No. 000816S), resigned as the company`s statutory auditors with effect from October 28, 2026, citing pre-occupation with other assignments and an inability to devote sufficient time to the company`s affairs. The resignation followed the auditors` appointment on October 10, 2026, to fill a casual vacancy previously held by M/s. Vasavi & Co., Chartered Accountants, and they confirmed they did not commence any audit or limited review work prior to their resignation.
Transgene Biotek Ltd 29 Oct 2026 12:00 AM
Transgene Biotek Limited confirms statutory auditor resignation, effective immediately, per filing,
Transgene Biotek Limited announced that M/s. Eswara Rao & Co., Chartered Accountants, have resigned as the company’s statutory auditors with immediate effect, citing pre-occupation with other assignments, according to a regulatory filing on October 29, 2026. The resignation was tendered in a letter dated October 28, 2026, and the company will take steps to appoint a new statutory auditor in accordance with applicable regulations.
Transgene Biotek Ltd 03 Oct 2026 12:00 AM
Transgene Biotek confirms no Non-Convertible Securities issuance for the September quarter,
Transgene Biotek Limited informed the BSE Limited that the company has not issued any Non-Convertible Securities, rendering Regulation 57(5) of the SEBI (LODR) Regulations, 2015 not applicable for the quarter ended September 30, 2026.
Subscribe for our
newsletter
Open Account Now